Abstract:Scientists working in translational oncology regularly conduct multigroup studies of mice with serially measured tumors. Longitudinal data collected can feature mid-study dropouts and complex nonlinear temporal response patterns. Parametric statistical models such as ones assuming exponential growth are useful for summarizing tumor volume over ranges for which the growth model holds, with the advantage that the model's parameter estimates can be used to summarize between-group differences in tumor volume growth with statistical measures of uncertainty. However, these same assumed growth models are too rigid to recapitulate patterns observed in many experiments, which in turn diminishes the effectiveness of their parameter estimates as summary statistics. To address this problem, we generalized such models by adopting a nonparametric approach in which group-level response trends for logarithmically scaled tumor volume are estimated as regression splines in a generalized additive mixed model. We also describe a novel summary statistic for group level splines over user-defined, experimentally relevant time ranges. This statistic reduces to the log-linear growth rate for data well described by exponential growth and also has a sampling distribution across groups that is well approximated by a multivariate Gaussian, thus facilitating downstream analysis. Real-data examples show that this nonparametric approach not only enhances fidelity in describing nonlinear growth scenarios but also improves statistical power to detect interregimen differences when compared with the simple exponential model so that it generalizes the linear mixed effects paradigm for analysis of log-linear growth to nonlinear scenarios in a useful way. SIGNIFICANCE: This work generalizes the statistical linear mixed modeling paradigm for summarizing longitudinally measured preclinical tumor volume studies to encompass studies with nonlinear and nonmonotonic group response patterns in a statistically rigorous manner.

Joint Modeling Tumor Burden and Time to Event Data in Oncology Trials.

Nonlinear Multilevel Joint Model for Individual Lesion Kinetics and Survival to Characterize Intra-Individual Heterogeneity in Patients with Advanced Cancer

Bayesian Dose Finding by Jointly Modelling Toxicity and Efficacy As Time-To-Event Outcomes

Bayesian Phase II Adaptive Randomization by Jointly Modeling Time-to-event Efficacy and Binary Toxicity

Bridging the gap between two‐stage and joint models: The case of tumor growth inhibition and overall survival models

A novel Bayesian generative approach for estimating tumor dynamics from published studies

Joint longitudinal and survival-cure models in tumour xenograft experiments.

Joint modeling of tumor dynamics and progression‐free survival in advanced breast cancer: Leveraging data from amcenestrant early phase I–II trials

Tumor growth and overall survival modeling to support decision making in phase Ib/II trials: A comparison of the joint and two-stage approaches

Joint Models for Time-to-Event Data and Longitudinal Biomarkers of High Dimension

Adaptive enrichment trial designs using joint modeling of longitudinal and time-to-event data

Joint longitudinal and time-to-event models for multilevel hierarchical data

A Joint Model Considering Measurement Errors for Optimally Identifying Tumor Mutation Burden Threshold

Comparison of Sequential and Joint Nonlinear Mixed Effects Modeling of Tumor Kinetics and Survival Following Durvalumab Treatment in Patients with Metastatic Urothelial Carcinoma

A Bayesian joint model for multivariate longitudinal and time-to-event data with application to ALL maintenance studies

Adaptive enrichment trial designs using joint modelling of longitudinal and time-to-event data

Optimal Bayesian Hierarchical Model to Accelerate the Development of Tissue-Agnostic Drugs and Basket Trials.

Comprehensive Joint Modeling of First-Line Therapeutics in Non-Small Cell Lung Cancer

A joint model for (un)bounded longitudinal markers, competing risks, and recurrent events using patient registry data

Generalized Additive Mixed Modeling of Longitudinal Tumor Growth Reduces Bias and Improves Decision Making in Translational Oncology

Statistical considerations in long-term efficacy evaluation of anti-cancer therapies